title: Critical illness-related bone loss is associated with osteoclastic and angiogenic abnormalities.
abstract: Critically ill patients are at increased risk of fractures during rehabilitation, and can experience impaired healing of traumatic and surgical bone fractures. In addition, markers of bone resorption are markedly increased in critically ill patients, while markers of bone formation are decreased. In the current study, we have directly investigated the effect of critical illness on bone metabolism and repair. In a human in vitro model of critical illness, Fluorescence-activated cell sorting (FACS) analysis revealed an increase in circulating CD14+/CD11b+ osteoclast precursors in critically ill patient peripheral blood compared to healthy controls. In addition, the formation of osteoclasts was increased in patient peripheral blood mononuclear cell (PBMC) cultures compared to healthy controls, both in the presence and absence of osteoclastogenic factors receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). Culturing PBMCs with 10% critically ill patient serum further increased osteoclast formation and activity in patient PBMCs only, and neutralization studies revealed that immunoglobulin G (IgG) antibody signaling through the immunoreceptor Fc receptor common γ chain III (FcRγIII) played an important role. When analyzing bone formation, no differences in osteogenic differentiation were observed using human periosteal-derived cells (hPDCs) treated with patient serum in vitro, but a decrease in the expression of vascular endothelial growth factor receptor 1 (VEGF-R1) suggested impaired vascularization. This was confirmed using serum-treated hPDCs implanted onto calcium phosphate scaffolds in a murine in vivo model of bone formation, where decreased vascularization and increased osteoclast activity led to a decrease in bone formation in scaffolds with patient serum-treated hPDCs. Together, these findings may help to define novel therapeutic targets to prevent bone loss and optimize fracture healing in critically ill patients.
authors.affiliation: Department and Laboratory of Intensive Care Medicine, Katholieke Universiteit Leuven, Leuven, Belgium. Helen.Owen@med.kuleuven.be
authors.forename: Helen C
authors.initials: HC
authors.lastname: Owen
authors.forename: Ineke
authors.initials: I
authors.lastname: Vanhees
authors.forename: Lien
authors.initials: L
authors.lastname: Solie
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Roberts
authors.forename: Andy
authors.initials: A
authors.lastname: Wauters
authors.forename: Frank P
authors.initials: FP
authors.lastname: Luyten
authors.forename: Sophie
authors.initials: S
authors.lastname: Van Cromphaut
authors.forename: Greet
authors.initials: G
authors.lastname: Van den Berghe
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D001847:Bone Diseases / Q000150:complications; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology*; D016638:Critical Illness; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D020869:Gene Expression Profiling; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry; D007963:Leukocytes, Mononuclear / Q000166:cytology; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic; D010010:Osteoclasts / Q000166:cytology*; D010012:Osteogenesis; D010521:Periosteum / Q000166:cytology; D017452:Receptors, IgG / Q000378:metabolism
chemical_list: C496124:FCGR3A protein, human; D007074:Immunoglobulin G; D017452:Receptors, IgG